Development Neuren Pharmaceuticals (NEU-ASX) | Speculative Buy | Valuation: AUD7.70This is a key result in line with our research thesis.Trofinetide (formerly NNZ-2566) is Neuren’s primary asset and has been exclusively licensed to Acadia Pharmaceuticals (NASDAQ:ACAD) for North America. Today Acadia announced a robustly positive Phase 3 clinical trial outcome.This result derisks NEU and adds ~40% to our valuation at initiation.
report
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.25 |
Change
-0.100(0.81%) |
Mkt cap ! $1.565B | |||
| Open | High | Low | Value | Volume |
| $12.20 | $12.25 | $12.02 | $3.677M | 302.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1579 | $12.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.26 | 1199 | 1 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |